GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Shares Outstanding (EOP)

Fusion Antibodies (LSE:FAB) Shares Outstanding (EOP) : 59.45 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Fusion Antibodies's shares outstanding for the quarter that ended in Sep. 2023 was 59.45 Mil.

Fusion Antibodies's quarterly shares outstanding increased from Mar. 2023 (26.01 Mil) to Sep. 2023 (59.45 Mil). It means Fusion Antibodies issued new shares from Mar. 2023 to Sep. 2023 .

Fusion Antibodies's annual shares outstanding stayed the same from Mar. 2022 (26.01 Mil) to Mar. 2023 (26.01 Mil).


Fusion Antibodies Shares Outstanding (EOP) Historical Data

The historical data trend for Fusion Antibodies's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Shares Outstanding (EOP) Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 22.09 22.09 25.61 26.01 26.01

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.92 26.01 26.01 26.01 59.45

Competitive Comparison of Fusion Antibodies's Shares Outstanding (EOP)

For the Biotechnology subindustry, Fusion Antibodies's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's Shares Outstanding (EOP) falls into.



Fusion Antibodies Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Fusion Antibodies  (LSE:FAB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Fusion Antibodies Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022